Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Interest & Investment Income (2021 - 2025)

Historic Interest & Investment Income for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $93765.0.

  • InMed Pharmaceuticals' Interest & Investment Income rose 6422.92% to $93765.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $192553.0, marking a year-over-year decrease of 5711.06%. This contributed to the annual value of $155882.0 for FY2025, which is 7047.14% down from last year.
  • InMed Pharmaceuticals' Interest & Investment Income amounted to $93765.0 in Q3 2025, which was up 6422.92% from $51687.0 recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Interest & Investment Income registered a high of $166760.0 during Q4 2023, and its lowest value of $5148.0 during Q3 2021.
  • Its 5-year average for Interest & Investment Income is $80357.5, with a median of $72587.0 in 2022.
  • In the last 5 years, InMed Pharmaceuticals' Interest & Investment Income skyrocketed by 131000.39% in 2022 and then crashed by 8636.15% in 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Interest & Investment Income (Quarter) stood at $26277.0 in 2021, then soared by 340.68% to $115797.0 in 2022, then skyrocketed by 44.01% to $166760.0 in 2023, then crashed by 81.69% to $30536.0 in 2024, then surged by 207.06% to $93765.0 in 2025.
  • Its last three reported values are $93765.0 in Q3 2025, $51687.0 for Q2 2025, and $16565.0 during Q1 2025.